Muthu Vaduganathan

@mvaduganathan

Cardiologist at Brigham and Women's Hospital | SoMe / CME Editor at | Views & content are my own

Boston, MA
Vrijeme pridruživanja: srpanj 2017.

Tweetovi

Blokirali ste korisnika/cu @mvaduganathan

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @mvaduganathan

  1. proslijedio/la je Tweet
    prije 10 sati

    LVEF & Sex SubAnalyses of PARAGON-HF & PARADIGM-HF 📍The effects SAC/VALvs RAASi, vary by LVEF with treatment benefits, particularly for HF 🏨, that appear to extend to 👥 with HFmrEF 📍These therapeutic benefits appeared to extend to a higher LVEF range in 🙍‍♀️vs 🙎🏻‍♂️

    , , i još njih 7
    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet

    Highly anticipated pooled analysis of PARADIGM-HF & PARAGON-HF by in . Key findings that will change my practice below!

    Prikaži ovu nit
    Poništi
  3. proslijedio/la je Tweet
    prije 19 sati

    : Substance and Substrate: LVEF and Sex Subgroup Analyses of PARAGON-HF and PARADIGM-HF Trials

    Poništi
  4. proslijedio/la je Tweet
    prije 20 sati

    : In combined PARADIGM/PARAGON-HF analysis, benefit of sacubitril/valsartan varies by LVEF, extends to . Read more:

    Poništi
  5. proslijedio/la je Tweet
    3. velj

    episode featuring corresponding author, & Senior Associate Editor, discussing Sacubitril/Valsartan Across Ejection Fraction Spectrum Featured Article:

    Poništi
  6. proslijedio/la je Tweet
    3. velj

    Insulin was discovered a century ago but prices remain high. The VA negotiates with manufacturers but Medicare, by law, cannot. What if Congress allowed Medicare to negotiate insulin prices like the VA? We identify substantial savings.

    Poništi
  7. proslijedio/la je Tweet
    30. sij

    HF is under-diagnosed, misdiagnosed, not captured even when diagnosed, or miscoded as another competing diagnosis even when accurately documented. Need changes in DRG concepts, education and accurate data for HF and HF outcomes.

    Poništi
  8. proslijedio/la je Tweet
    29. sij

    Additional risk model for HFrEF. The key question that remains is whether or not application of HF risk models in clinical practice improves referral, quality, and pt-centered outcomes.

    Poništi
  9. proslijedio/la je Tweet
    29. sij

    📌Isolated Diastolic Hypertension as defined by the 2017 ACC/AHA blood pressure guideline may not be associated with increased risk for cardiovascular outcomes 📂

    , , i još njih 7
    Poništi
  10. proslijedio/la je Tweet
    29. sij

    New research suggests as many as TWO million heart patients are using marijuana. Dr. Fred Feit is LIVE on Heart to Heart talking with study author about what we know - and what we don't - about how marijuana affects cardiac health. 877-698-3627

    Poništi
  11. proslijedio/la je Tweet
    27. sij

    Thrilled to share our manuscript published in today - Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial | Circulation

    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet
    27. sij

    Effect of on the first and total number of AF/AFL events in patients with/o AF/AFL⤵️ ⤵️ the incidence of episodes of AF/AFL adverse events in high-risk patients with T2DM 📍effect was consistent regardless of prior history of AF, ASCVD, or HF.

    , , i još njih 7
    Prikaži ovu nit
    Poništi
  13. proslijedio/la je Tweet
    26. sij
    Poništi
  14. proslijedio/la je Tweet
    25. sij

    Just in - "30-Day Non-Index Readmissions and Clinical Outcomes Following Cardiac Surgery" We discuss important implications of cardiac surgery care fragmentation

    , , i još njih 7
    Poništi
  15. proslijedio/la je Tweet
    25. sij

    In 2017, Medicare Part D spent $22B on DM therapies. Which ones were costliest to ? New study examines trends of insulin & non-insulin spending

    Poništi
  16. 24. sij
    Poništi
  17. proslijedio/la je Tweet
    24. sij

    In our Viewpoint now online , we discuss current concerns regarding the supply of heparin and implications+contingencies in the event of a critical shortage. 1/

    Prikaži ovu nit
    Poništi
  18. proslijedio/la je Tweet
    22. sij

    New Research Letter from Drs. , , et al. sought to compare the performance of the GRACE, TIMI, and TARRACO scores in patients with type 2 . Read their findings in the newest issue:

    Poništi
  19. proslijedio/la je Tweet
    22. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    Patients without any prior hospitalization for HF were of such low risk did they even have HFpEF? Does this explain why RTC enrolled patients with HFpEF have had much better prognosis compare to HFrEF whereas registry and community cohort studies show little to no difference?

    Poništi
  20. proslijedio/la je Tweet
    22. sij

    Biomarkers to qualify drugs, as endpoints, and to inform mechanism: quite a day planned.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·